首页>投融资
Aktis Oncology
B轮
Aktis Oncology是一家生物技术公司，致力于发现和开发新型靶向放射性药物，以治疗广泛的实体肿瘤癌症。Aktis是由MPM Capital和其经验丰富的企业家和药物开发团队创建和孵化的，开发了专有平台，生产具有理想性能的肿瘤靶向药物的放疗。针对高穿透性和长停留时间的设计，Aktis Oncology的分子可以快速清除身体的其他区域，从而最大限度地消除肿瘤，同时最大限度地减少治疗的副作用。这些疗法也能使临床医生在暴露于治疗性放射性同位素之前，对目标进行可视化和验证。
基本信息
-
公司全称Aktis Oncology Inc
-
类型新型靶向放射性药物开发商
-
产业领域药品研发/制造、生物药
-
公司人数15人以下
-
地址
-
联系电话（443） 213-0505
-
邮箱info@aktisoncology.com
-
成立时间2021-01-01
投融资
-
2024-09-30B轮1.75亿美元RTW InvestmentsJanus Henderson InvestorsRA Capital百时美施贵宝Eli LillyT. Rowe PriceAvidity PartnersMRL Ventures Fund
-
2022-08-25A轮8400万美元Merck GroupVida Ventures诺华Mirae Asset Venture InvestmentsPappas CapitalTCG X百时美施贵宝MPM CapitalEcoR1 CapitalCowen Healthcare InvestmentsMRL Ventures FundTimefolio CapitalArrowMark Partners八方资本
-
2021-03-18A轮7200万美元Vida Ventures诺华百时美施贵宝MPM CapitalEcoR1 CapitalTCG Crossover Fund I八方资本
相关投融资企业
捐赠/众筹/授予
igaTx 是一家生物技术公司，开发工程化单体 IgA 中性粒细胞接合器，以释放中性粒细胞对癌症的肿瘤杀伤能力，以及针对传染病的工程化二聚体 IgA 杀伤能力。该公司在工程治疗性 IgA 方面的前沿方法基于 Jeanette Leusen 教授在乌得勒支医学中心（荷兰乌得勒支）进行的开创性工作，并广泛适用于许多不同疾病。
C轮
SiteOne Therapeutics, founded by Stanford University, is a biotechnology company focused on the development of long-acting analgesics, non-norcotic analgecis and diagnostic imaging agents for pain and cancer.In May 2023, SiteOne Therapeutics Inc received a grant for up to $15 million from the National Institute on Drug Abuse.In January 2017, the company raised $15 million in a series B round of financing
A轮
PsiOxus Therapeutics Ltd was formed from the merger of Myotec Therapeutics and Hybrid BioSystems in December 2010. The company is focused on the development of novel therapeutics that address cancer and other clinically unmet diseases.Myotec Therapeutics was a spin-out from Imperial Innovations and was set up to develop technology originated at Imperial College London. It focused on repurposing drugs for the treatment of cachexia, with the intention of out-licensing after completion of phase II studies.In June 2017, the company expanded its operations into a 21,000 sq ft state-of-the-art facility on the Abingdon Science Park in Oxfordshire, UK and a new US facility in Plymouth Meeting near Philadelphia, PA.In April 2012, PsiOxus announced that it would expand into new facilities at the Milton Park in Oxfordshire, UK. The expansion would include a bespoke laboratory for the research and development of novel viral therapeutics; later that month, the facility was opened.By Decem
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息